MXCT — MaxCyte, Inc.

Summary of MaxCyte (MXCT) Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $9.7 million, down 7% from $10.4 million in Q1 2025.
• Core Revenue: $6.2 million, a 25% decrease from $8.2 million in the prior year.
  • Instrument Revenue: $1.3 million (down from $1.4 million).
  • License Revenue: $2.1 million (down from $2.5 million).
  • Processing Assembly Revenue: $2.3 million (down from $3.9 million).
• SPL Program Related Revenue: $3.4 million, up from $2.1 million in Q1 2025, driven by a $3 million milestone from a clinical customer.
• Gross Margin: 84%, down from 86% in Q1 2025; non-GAAP adjusted gross margin at 78%.
• Operating Expenses: $14.3 million, significantly reduced from $21.2 million in Q1 2025, reflecting restructuring efforts.
• Cash Position: $147.7 million in cash equivalents and no debt.
• Share Repurchase Program: Authorized up to $10 million.

2. Strategic Updates and Business Highlights

• SPL Partnerships: Maintained 29 SPL partners with 30+ clinical and preclinical programs. Five clinical programs are expected to launch commercially in 2027-2028.
• ExPERT DTX Launch: Early traction noted in adoption for cell therapy development and protein screening, with expectations for increased sales in the second half of 2026.
• SeQure Progress: Generated $600,000 in revenue, showing significant year-over-year growth and potential for further expansion as FDA guidance supports off-target risk assessment.
• Clinical Development: Encouraging progress in the cell and gene therapy landscape, particularly for later-stage programs.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Reiterated total revenue expectation of $30 million to $32 million, with core revenue of $25 million to $27 million and SPL milestones/royalties of $5 million.
• Core Revenue Growth: Expected to be weighted towards the second half of 2026, with no additional milestones forecasted for the remainder of the year.

4. Challenges and Points of Concern

• Core Revenue Decline: Significant drop in core revenue attributed to inventory management by the largest SPL customer and discontinued SPL programs.
• Market Conditions: Ongoing challenges in the early-stage clinical funding environment, although stability noted in later-stage programs.
• Gross Margin Pressure: Slight decline in gross margin due to inventory adjustments and SPL customer challenges.

5. Notable Q&A Insights

• Cautious Guidance on Milestones: Management indicated that the absence of additional milestone revenue forecasts is due to contractual structures tied to dosing timings rather than trial initiation.
• Sales Funnel and Licensing: Management remains optimistic about signing 3-5 new SPL partners in 2026 despite the absence of new agreements in the first half.
• SeQure's Contribution: Anticipated continued growth in SeQure revenue, with confidence in its role as a standard for off-target risk assessment.
• Market Dynamics: Management noted a healthier focus on late-stage clinical programs, with increased financing activity for companies advancing lead assets.

Overall, while MaxCyte faces challenges in core revenue and market conditions, strategic initiatives and a strong cash position provide a foundation for future growth.